,0
symbol,ACRS
price,3.77
beta,1.45233
volAvg,421544
mktCap,161805760
lastDiv,0.0
range,0.7-5.04
changes,0.1
companyName,Aclaris Therapeutics Inc
currency,USD
cik,0001557746
isin,US00461U1051
cusip,00461U105
exchange,Nasdaq Global Select
exchangeShortName,NASDAQ
industry,Biotechnology
website,https://www.aclaristx.com/
description,"Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company is headquartered in Wayne, Pennsylvania and currently employs 169 full-time employees. The firm is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The firm is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer. The Companyâ€™s drug discovery platform KINect technology is a kinase-focused drug discovery engine utilizing computational chemistry to integrate proprietary compound collections and highly experienced biologists and medicinal chemists to identify and advance potential candidates into preclinical and clinical development."
ceo,Dr. Neal Walker
sector,Healthcare
country,US
fullTimeEmployees,77
phone,14843247933
address,640 Lee Rd Ste 200
city,Wayne
state,PENNSYLVANIA
zip,19087
dcfDiff,-6.4
dcf,5.11964
image,https://financialmodelingprep.com/image-stock/ACRS.png
ipoDate,2015-10-07
defaultImage,False
